Artesunate, a potential drug for treatment of Babesia infection

Parasitology International

Volumn 59, Issue 3, 2010, Pages 481-486

  Goo, Youn Kyoung ^a   Terkawi, M Alaa ^a   Jia, Honglin ^a   Aboge, G Oluga ^a   Ooka, Hideo ^a   Nelson, Bryce ^a   Kim, Suk ^b   Sunaga, Fujiko ^c   Namikawa, Kazuhiko ^c   Igarashi, Ikuo ^a   Nishikawa, Yoshifumi ^a   Xuan, Xuenan ^a  

^a OBIHIRO UNIVERSITY OF AGRICULTURE AND VETERINARY MEDICINE   (Japan)

^b Gyeongsang National University   (South Korea)

^c AZABU UNIVERSITY   (Japan)

Author keywords

Artesunate; Babesia bovis; Babesia gibsoni; Babesia microti

Indexed keywords

ARTESUNATE; ATOVAQUONE; DIMINAZENE ACETURATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BABESIA; BABESIA BOVIS; BABESIA GIBSONI; BABESIA MICROTI; BABESIOSIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; FEMALE; GROWTH INHIBITION; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ARTESUNATE; BABESIA; BABESIA BOVIS; BABESIA GIBSONI; BABESIA MICROTI; MUS;

EID: 77955336014     PISSN: 13835769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.parint.2010.06.004     Document Type: Article

References (36)

1. Homer M.J., Aguilar-Delfin I., Telford S.R., Krause P.J., Persing D.H. Babesiosis. Clin Microbiol Rev 2000, 13:451-469.
2. Vial H.J., Gorenflot A. Chemotherapy against babesiosis. Vet Parasitol 2006, 138:147-160.
3. Hien T.T., White N.J. Qinghaosu. Lancet 1993, 341:603-608.
4. ter Kuile F., White N.J., Holloway P., Pasvol G., Krishna S. Plasmodium falciparum: in vitro studies of the pharmacodynamic properties of drugs used for the treatment of severe malaria. Exp Parasitol 1993, 76:85-95.
5. McGready R., Cho T., Cho J.J., Simpson J.A., Luxemburger C., Dubowitz L., et al. Artemisinin derivatives in the treatment of falciparum malaria in pregnancy. Trans R Soc Trop Med Hyg 1998, 92:430-433.
6. Price R., van Vugt M., Phaipun L., Luxemburger C., Simpson J., McGready R., et al. Adverse effects in patients with acute falciparum malaria treated with artemisinin derivatives. Am J Trop Med Hyg 1999, 60:547-555.
7. Golenser J., Waknine J.H., Krugliak M., Hunt N.H., Grau G.E. Current perspectives on the mechanism of action of artemisinins. Int J Parasitol 2006, 36:1427-1441.
8. Nontprasert A., Nosten-Bertrand M., Pukrittayakamee S., Vanijanonta S., Angus B.J., White N.J. Assessment of the neurotoxicity of parenteral artemisinin derivatives in mice. Am J Trop Med Hyg 1998, 59:519-522.
9. Ashley E.A., White N.J. Artemisinin-based combinations. Curr Opin Infect Dis 2005, 18:531-536.
10. Nagai A., Yokoyama N., Matsuo T., Bork S., Hirata H., Xuan X., et al. Growth-inhibitory effects of artesunate, pyrimethamine, and pamaquine against Babesia equi and Babesia caballi in in vitro cultures. Antimicrob Agents Chemother 2003, 47:800-803.
11. Marley S.E., Eberhard M.L., Steurer F.J., Ellis W.L., McGreevy P.B., Ruebush T.K. Evaluation of selected antiprotozoal drugs in the Babesia microti-hamster model. Antimicrob Agents Chemother 1997, 41:91-94.
12. Pudney M., Gray J.S. Therapeutic efficacy of atovaquone against the bovine intraerythrocytic parasite, Babesia divergens. J Parasitol 1997, 83:307-310.
13. Gray J.S., Pudney M. Activity of atovaquone against Babesia microti in the Mongolian gerbil, Meriones unguiculatus. J Parasitol 1999, 85:723-728.
14. Wittner M., Lederman J., Tanowitz H.B., Rosenbaum G.S., Weiss L.M. Atovaquone in the treatment of Babesia microti infections in hamsters. Am J Trop Med Hyg 1996, 55:219-222.
15. Hughes W.T., Oz H.S. Successful prevention and treatment of babesiosis with atovaquone. J Infect Dis 1995, 172:1042-1046.
16. Akiba M., Saeki H., Ishii T., Yamamoto S., Ueda K. Immunological changes in Babesia rodhaini infected BALB/c mice after treated with anti-babesial drug; diminazene diaceturate. J Vet Med Sci 1991, 53:371-377.
17. Yeruham I., Avidar Y., Aroch I., Hadani A. Intra-uterine infection with Babesia bovis in a 2-day-old calf. J Vet Med B Infect Dis Vet Public Health 2003, 50:60-62.
18. Gray J.S. Chemotherapy of Babesia divergens in the gerbil, Meriones unguiculatus. Res Vet Sci 1983, 35:318-324.
19. Levy M.G., Ristic M. Babesia bovis: continuous cultivation in a microaerophilous stationary phase culture. Science 1980, 207:1218-1220.
20. Sunaga F., Namikawa K., Kanno Y. Continuous in vitro culture of erythrocytic stages of Babesia gibsoni and virulence of the cultivated parasite. J Vet Med Sci 2002, 64:571-575.
21. Portugal J. Berenil acts as a poison of topoisomerase II. FEBS Lett 1994, 344:136-138.
22. Kuttle K.L., Johnson L.W. Chemoprophylactic activity of imidocarb, diminazene and oxytetracycline against Babesia bovis and B. bigemina. Vet Parasitol 1986, 21:107-118.
23. Fry M., Pudney M. Site of action of the antimalarial hydroxynaphthoquinone, 2-[trans-4-(4'-chlorophenyl) cyclohexyl]-3-hydroxy-1, 4-naphthoquinone (566C80). Biochem Pharmacol 1992, 43:1545-1553.
24. Eckstein-Ludwig U., Webb R.J., Van Goethem I.D., Lee A.G., Kimura M., O'Neill P.M., et al. Artemisinins target the SERCA of Plasmodium falciparum. Nature 2003, 424:957-961.
25. Ruebush T.K., Rubin R.H., Wolpow E.R., Cassaday P.B., Schultz M.G. Neurologic complications following the treatment of human Babesia microti infection with diminazene aceturate. Am J Trop Med Hyg 1979, 28:184-189.
26. Milner R.J., Reyers F., Taylor J.H., van der Berg J.S. The effect of diminazene aceturate in cholinesterase activity in dogs with canine babesiosis. J S Afr Vet Assoc 1997, 68:111-113.
27. Taboada J. Babesiosis pp. 473-481. In: Infectious diseases of the dog and cat (Creene, C.E. ed.), Saunders, Philadelphia, PA.
28. Farwell G.E., Legrand E.K., Cobb C.C. Clinical observations on Babesia gibsoni and Babesia canis infections in dogs. J Am Vet Med Assoc 1982, 180:507-511.
29. Anari M.R., Creighton M.D., Ngui J.S., Tschirret-Guth R.A., Teffera Y., Doss G.A., et al. Species differences in metabolism and pharmacokinetics of a sphingosine-phosphate receptor agonist in rats and dogs: formation of a unique glutathione adduct in the rat. Drug Metab Dispos 2006, 34:1367-1375.
30. Parke D.V. Species differences in pharmacokinetics. Vet Res Commun 1983, 7:285-300.
31. Whegang S.Y., Tahar R., Foumane V.N., Soula G., Gwet H., Thalabard J.C., et al. Efficacy of non-artemisinin- and artemisinin-based combination therapies for uncomplicated falciparum malaria in Cameroon. Malar J 2010, 9:56.
32. Ilett K.F., Batty K.T., Powell S.M., Binh T.Q., Thu le T.A., Phuong H.L., et al. The pharmacokinetic properties of intramuscular artesunate and rectal dihydroartemisinin in uncomplicated falciparum malaria. Br J Clin Pharmacol 2002, 53:23-30.
33. Brewer T.G., Grate S.J., Peggins J.O., Weina P.J., Petras J.M., Levine B.S., et al. Fatal neurotoxicity of arteether and artemether. Am J Trop Med Hyg 1994, 51:251-259.
34. Brewer T.G., Peggins J.O., Grate S.J., Petras J.M., Levine B.S., Weina P.J., et al. Neurotoxicity in animals due to arteether and artemether. Trans R Soc Trop Med Hyg 1994, 88:33-36.
35. Petras J.M., Kyle D.E., Gettayacamin M., Young G.D., Bauman R.A., Webster H.K., et al. Arteether: risks of two-week administration in Macaca mulatta. Am J Trop Med Hyg 1997, 56:390-396.
36. Nontprasert A., Pukrittayakamee S., Dondorp A.M., Clemens R., Looareesuwan S., White N.J. Neuropathologic toxicity of artemisinin derivatives in a mouse model. Am J Trop Med Hyg 2002, 67:423-429.